Acumen Pharmaceuticals, Inc. Interest Expense Nonoperating
Acumen Pharmaceuticals, Inc. (ABOS) reported Interest Expense Nonoperating of $1.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $1.09M, a 4.59% increase year-over-year.
- Acumen Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $1.07M, a 4.50% increase year-over-year.
- Acumen Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.09M, a 4.82% increase year-over-year.
- Acumen Pharmaceuticals, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $1.07M, a 3.99% increase year-over-year.
- Acumen Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2025 was $4.22M, a 3.83% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2024 was $4.07M, a 600.17% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. interest expense nonoperating for fiscal 2023 was $581.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.09M 10-Q · filed 2026-08-12 | $2.16M 10-Q · filed 2026-08-12 | $3.25M derived: sum of 3 quarters · filed 2026-08-12 | $4.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-12 | $2.16M derived: sum of 2 quarters · filed 2026-05-12 | $3.22M derived: sum of 3 quarters · filed 2026-05-12 | $4.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.15M derived: sum of 2 quarters · filed 2026-03-26 | $3.20M derived: sum of 3 quarters · filed 2026-08-12 | $4.22M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.07M 10-Q · filed 2025-11-12 | $2.11M derived: sum of 2 quarters · filed 2026-08-12 | $3.14M 10-Q · filed 2025-11-12 | $4.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.05M 10-Q · filed 2026-08-12 | $2.07M 10-Q · filed 2026-08-12 | $3.11M derived: sum of 3 quarters · filed 2026-08-12 | $4.13M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.02M 10-Q · filed 2026-05-12 | $2.06M derived: sum of 2 quarters · filed 2026-05-12 | $3.09M derived: sum of 3 quarters · filed 2026-05-12 | $4.09M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.06M derived: sum of 2 quarters · filed 2026-03-26 | $3.07M derived: sum of 3 quarters · filed 2026-03-26 | $4.07M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.03M 10-Q · filed 2025-11-12 | $2.03M derived: sum of 2 quarters · filed 2025-11-12 | $3.03M 10-Q · filed 2025-11-12 | $3.61M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.00M 10-Q · filed 2025-08-12 | $2.00M 10-Q · filed 2025-08-12 | $2.58M derived: sum of 3 quarters · filed 2025-08-12 | $2.58M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.00M 10-Q · filed 2025-05-13 | $1.58M derived: sum of 2 quarters · filed 2025-05-13 | $1.58M derived: sum of 3 quarters · filed 2025-05-13 | $1.58M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $581.00K derived: sum of 2 quarters · filed 2025-03-27 | $581.00K derived: sum of 3 quarters · filed 2025-03-27 | $581.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |